FDA Approves New Treatment Jevtana (cabazitaxel) for Advanced Prostate Cancer
The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.
Vitamin D Status is Not Associated with Risk for Less Common Cancers
Despite hopes that higher blood levels of
vitamin D might reduce cancer risk, a large study finds no protective effect against non-Hodgkin lymphoma or cancer of the endometrium, esophagus, stomach, kidney, ovary, or pancreas. In this study, carried out by researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and many other research institutions, data based on blood samp...
Markers on Human Breast Cancer Cells Linked to Development of an Aggressive Form of the Cancer
Scientists have identified a group of surface markers on cells linked to an aggressive type of breast cancer called estrogen receptor-negative cancer. In this preliminary study, estrogen-negative breast cancer developed when three markers, CD44+, CD49fhi, and CD133hi were present simultaneously on the surface of human cells taken from breast cancer patients and transplanted into a mouse; this is called a xenograft model. The scientists named these human cells with tumor-forming ability in mic...
Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer
Scientists have established the presence of certain proteins in ovarian cancer tissues and have linked these proteins to poor survival rates in women with advanced stages of the disease. The study, led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appears in Cancer online, April 19, 2010.
Pathways that Can Repair Brca1 Breast Cancer Gene Mutation Clarified in Mice
In a new study in mice, scientists have compensated for mutations in the Brca1 gene that can lead to cancer by deleting a second gene, which then lessens the probability of cancer. Mice Brca1-associated mammary tumors have significant similarities to human BRCA1- associated (BReast CAncer 1, early onset) breast cancer in regard to tumor aggressiveness, high incidence, mutations and genetic instability. The study, led by scientists at National Cancer Institute (NCI), part of the National Insti...
Information on Life after Cancer Now Available on NIHSeniorHealth.gov
Older adults who have survived cancer can find out what to expect once treatment ends in Life after Cancer, the newest topic on NIHSenior Health. Visitors to the site will learn about managing follow-up care, physical and emotional changes, and relationships with family and friends. The topic also addresses how a person's age and health status can affect recovery and survival. This is important information for older adults who make up about 60 percent of cancer survivors and whose cancer tre...
Abnormal Glycoprotein Antibodies Identified as Possible Biomarkers for Cancer
| Feb 22nd of 2010 |
Diseases
Cancer FEATURED |
Scientists have found that cancer patients produce antibodies that target abnormal glycoproteins (proteins with sugar molecules attached) made by their tumors. The result of this work suggests that antitumor antibodies in the blood may provide a fruitful source of sensitive biomarkers for cancer detection. The study, supported in part by the National Cancer Institute (NCI), part of the National Institutes of Health, appears in the Feb. 15, 2010 issue of the journal Cancer Research.
FDA Approves Rituxan (Rituximab) to Treat Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs, fludarabine and cyclophosphamide.
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The NIH Common Fund's Human Microbiome Project
The Shell Egg Rule - Protecting the Public From Salmonella Contamination
The Public Health Impact of Tobacco Product and Advertising Regulation
Read more
